Wedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Equities researchers at Wedbush cut their Q2 2025 earnings per share (EPS) estimates for Xencor in a report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). Wedbush currently has a "Outperform" rating and a $31.00 price target on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Wedbush also issued estimates for Xencor's Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.03) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.80) EPS, Q3 2026 earnings at ($0.80) EPS, FY2026 earnings at ($3.20) EPS, FY2027 earnings at ($3.39) EPS, FY2028 earnings at ($4.29) EPS and FY2029 earnings at ($5.95) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million for the quarter, compared to analysts' expectations of $23.44 million. During the same period last year, the business earned ($1.11) earnings per share. The company's quarterly revenue was up 104.6% on a year-over-year basis.

Several other research firms have also recently commented on XNCR. William Blair started coverage on Xencor in a research report on Monday, April 21st. They set an "outperform" rating on the stock. Barclays dropped their price objective on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research report on Thursday. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Finally, Wells Fargo & Company decreased their price objective on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.50.

Xencor Trading Down 5.2%

Xencor stock opened at $8.33 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor has a one year low of $7.16 and a one year high of $27.24. The stock has a market capitalization of $592.70 million, a PE ratio of -2.60 and a beta of 0.99. The business's fifty day moving average is $10.73 and its 200 day moving average is $17.61.

Insider Activity at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the transaction, the executive vice president now owns 49,169 shares in the company, valued at $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.76% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xencor

A number of large investors have recently bought and sold shares of XNCR. Barclays PLC lifted its holdings in shares of Xencor by 100.7% in the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock worth $3,128,000 after buying an additional 78,066 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Xencor by 10.7% in the 4th quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company's stock worth $1,625,000 after buying an additional 6,810 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Xencor in the 4th quarter worth $632,000. Raymond James Financial Inc. bought a new position in shares of Xencor in the 4th quarter worth $2,329,000. Finally, Principal Financial Group Inc. raised its position in shares of Xencor by 16.5% in the 4th quarter. Principal Financial Group Inc. now owns 340,145 shares of the biopharmaceutical company's stock worth $7,817,000 after acquiring an additional 48,229 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.